Hong Kong DengYue Medicine News – October 30, 2025 – Lepu Biopharma Co., Ltd. (“Lepu Bio”) announced that its self-developed innovative antibody-drug conjugate (ADC)—Becotatug Vedotin for Injection (trade name: Meiyouheng®)—has been formally approved for marketing by the National…
For approximately 5.6 million patients worldwide living with progressive pulmonary fibrosis (PPF), every breath is accompanied by the relentless and irreversible scarring of their lungs. This is a fatal pulmonary disease, with nearly half of…
China’s breast cancer treatment landscape has reached a new milestone with the regulatory approval of the globally innovative antibody–drug conjugate Datopotamab Deruxtecan (Datroway). Official Approval: Defined Indication and Clinical Positioning On August 22, 2025, the…
The year 2025 marked a profound paradigm shift for China’s innovative drug industry. We witnessed the historic achievement of the “Dual Harvest for China Innovative Drugs.” ✨ The “Dual Harvest” signifies: 1️⃣ lies the scientific voice defining global…
The National Medical Products Administration (NMPA) of China has officially approved Tibremciclib Capsules (BPI-16350, brand name Kangmeina) developed by Betta Pharmaceuticals. ✅ This innovative Class 1 drug is indicated in combination with fulvestrant for adult…
China’s National Medical Products Administration (NMPA) has officially approved Luvometinib Tablets (brand name Fumaining®, development code FCN-159), an innovative Class 1 new drug developed by Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ✨ The approval was granted…
Recently, Fujian Shengdian Pharmaceutical Co., Ltd., a subsidiary of Hengrui Medicine, received approval from the National Medical Products Administration (NMPA) for the launch of Fosrolapitant and Palonosetron Hydrochloride Injection. 💊 This novel Class 1 innovative…
How strong is China innovative drug industry? The answer is increasingly evident as the nation now contributes nearly one-third of all drug candidates under development worldwide. China’s innovative drug industry is rising at unprecedented speed,…
May 29, 2025 — The National Medical Products Administration (NMPA) has granted conditional approval through a priority review pathway for Zanidatamab Injection (brand name: ZIIHERA), developed by BeiGene (Suzhou) Biologics Co., Ltd. 👉 The medication…
China’s National Medical Products Administration (NMPA) has officially approved Inpegsomatropin Injection, a first-in-class, innovative long-acting growth hormone developed by Xiamen Amoytop Biotech Co., Ltd., for the treatment of growth hormone deficiency (GHD) in children aged…
The National Medical Products Administration (NMPA) has officially approved the Class 1 innovative drug Trastuzumab Rezetecan Injection (brand name Aiweida). The drug was independently developed by Suzhou Suncadia Biopharma Co., Ltd. 👉 It is approved…
Source: DengYueMed On October 18, Chen Yuqing, Chairman of Fosun Pharma, stated at an event that China’s innovative drug industry has made a qualitative leap over the past decade. Since 2014, China’s share of global…
